U.S. Stem Cell, Inc.【USRM】
時価総額
$6.4万
PER
再生医療・細胞療法の新興企業。1999年8月設立。MyoCellやAdipocell、医師向け研修・幹細胞キットを展開。2017年3月のNorthstar和解。2022年12月31日時点で現金5,133ドルの報告。米国中心の展開。
| 2011年 12月31日 | 2012年 12月31日 | 2013年 12月31日 | 2014年 12月31日 | 2015年 12月31日 | 2016年 12月31日 | 2017年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | |
| NET LOSS | -4,697,037 | -4,016,467 | -3,143,259 | -2,253,511 | -1,641,880 | -2,070,386 | -3,481,491 | -2,160,427 | - | -2,890,493 | -3,287,416 | -2,857,943 |
| Bad debt (recoveries) | 166,266 | 166,266 | 166,266 | 28,732 | 38,599 | 5,640 | 16,740 | 62,207 | - | - | 93,241 | 616 |
| Interest and amortization of debt discount | 1 | 2 | 2 | 546,970 | 818,404 | 675,650 | 126,436 | 195,967 | - | 447,380 | 977,386 | 685,326 |
| Gain (loss) on settlement of accounts payable and accrued interest, net | - | - | - | - | - | - | - | - | - | - | - | 12 |
| Gain (loss) on debt extinguishment | - | - | 1 | 2 | 3 | 53,690 | -126,457 | 5,625 | - | 182 | -151,410 | -447,494 |
| Related party notes payable issued for services rendered | - | - | - | - | -59,850 | - | -316,800 | - | - | - | -422,722 | -750,000 |
| Share-based compensation | 10 | 10 | 10 | 537,606 | 1 | 410,002 | 645,483 | 1 | - | 701,939 | 556,556 | 384,380 |
| Accounts receivable | 4,760 | 2,607 | 21,178 | 104,228 | -21,778 | -13,367 | 43,674 | 37,283 | - | 5,956 | 40,290 | 3,735 |
| Inventories | 63,703 | 62,954 | -62,953 | - | 17,406 | 24,812 | 28,146 | 22,851 | - | -2,678 | -5,025 | 587 |
| Accounts payable | 3 | 3 | 3 | 858,437 | 434,490 | 10,464 | 469,220 | 426,263 | - | 149,521 | 73,195 | 274,268 |
| Accrued expenses | 5 | 7 | 7 | 313,601 | 365,525 | 224,188 | 435,390 | 226,673 | - | 18,347 | -6,768 | 18,341 |
| Contract liabilities | - | - | - | - | - | - | - | - | - | - | - | -3,000 |
| Net cash used in operating activities | - | - | - | - | -844,690 | 112,242 | 1 | 602,467 | - | -478,886 | -1,057,939 | -304,852 |
| Proceeds from sale of common shares | 63 | 64 | 65 | 479,625 | 582,808 | 60,000 | 275,000 | 367,700 | - | - | 275,000 | 85,000 |
| Proceeds from related party advances | - | - | - | - | 13,606 | 15,000 | - | 130,000 | - | 349,688 | 90,000 | 186,210 |
| Repayments of notes payable | 4 | 4 | 4 | 232,956 | 266,047 | 386,347 | 530,178 | 656,468 | - | 45,712 | 52,238 | 17,618 |
| Proceeds from convertible note payable | - | - | - | - | - | - | - | - | - | 45,000 | 766,000 | 27,000 |
| Repayments of convertible note payable | - | - | - | - | - | - | - | - | - | - | - | 10,000 |
| Net cash provided by financing activities | - | - | - | - | 1 | -54,995 | -1,239,152 | -543,820 | - | 497,456 | 1 | 270,592 |
| Net increase (decrease) in cash and cash equivalents | - | - | - | - | - | - | - | - | - | 18,570 | 20,823 | -34,260 |
| Interest paid | - | - | - | - | - | - | - | 1 | - | 40,989 | 22,762 | 6,113 |
| Income taxes paid | - | - | - | - | - | - | - | - | - | - | - | - |
| Modified retrospective adoption of ASU 2020-06 | - | - | - | - | - | - | - | - | - | - | - | 384,174 |
| Common shares issued | - | - | - | - | - | - | - | - | - | - | - | 48,817 |
| Common shares issued upon conversion of convertible notes and accrued interest | - | - | - | - | - | - | - | - | - | - | 375,586 | 25,000 |
| Common shares issued as equity kicker for convertible notes payable | - | - | - | - | - | - | - | - | - | - | - | 18,563 |
| Common stock issued in lieu of interest | 177,901 | 271,110 | 499,767 | 705,710 | 528,915 | 193,946 | - | - | - | - | 19,800 | 19,511 |
| Monthly payments on notes payable made on behalf of the Company | - | - | - | - | - | - | - | 189,909 | - | - | - | 8,250 |
| Beneficial conversion feature recognized on convertible note | - | - | - | - | - | - | - | - | - | 15,000 | 641,688 | - |